Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib

INTRODUCTION: The use of orally available BRAF kinase inhibitor – vemurafenib is associated with numerous adverse skin reactions. AIM: To assess the safety and early side effects of vemurafenib treatment in the unselected group of patients treated at the outpatient clinic, in particular the assessme...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowara, Elzbieta, Huszno, Joanna, Slomian, Grzegorz, Nieckula, Jaroslaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793055/
https://www.ncbi.nlm.nih.gov/pubmed/26985180
http://dx.doi.org/10.5114/pdia.2015.48045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793055/
https://www.ncbi.nlm.nih.gov/pubmed/26985180
http://dx.doi.org/10.5114/pdia.2015.48045

Ejemplares similares